Neogen Corporation Revenue
Neogen Corporation (NEOG) reported Revenue of $870.40 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- Neogen Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-05-31 was $225.30M, a 0.09% decline year-over-year.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-02-28 was $211.20M, a 4.43% decline year-over-year.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-11-30 was $224.69M, a 2.84% decline year-over-year.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-08-31 was $209.19M, a 3.58% decline year-over-year.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for fiscal 2026 was $870.40M, a 2.72% decline from fiscal 2025.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for fiscal 2025 was $894.70M, a 3.19% decline from fiscal 2024.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for fiscal 2024 was $924.20M, a 12.37% increase from fiscal 2023.
- Neogen Corporation revenue from contract with customer, excluding assessed tax for fiscal 2023 was $822.45M, a 56.01% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $225.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $436.50M derived: sum of 2 quarters · filed 2026-07-30 | $661.19M derived: sum of 3 quarters · filed 2026-07-30 | $870.40M 10-K · filed 2026-07-30 | ||||
| 2026-02-28 | $211.20M 10-Q · filed 2026-04-09 | $435.89M derived: sum of 2 quarters · filed 2026-04-09 | $645.10M 10-Q · filed 2026-04-09 | $870.58M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-11-30 | $224.69M 10-Q · filed 2026-01-08 | $433.88M 10-Q · filed 2026-01-08 | $659.38M derived: sum of 3 quarters · filed 2026-07-30 | $880.38M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-08-31 | $209.19M 10-Q · filed 2025-10-09 | $434.69M derived: sum of 2 quarters · filed 2026-07-30 | $655.69M derived: sum of 3 quarters · filed 2026-07-30 | $886.95M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-05-31 | $225.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $446.50M derived: sum of 2 quarters · filed 2026-07-30 | $677.76M derived: sum of 3 quarters · filed 2026-07-30 | $894.70M 10-K · filed 2026-07-30 | $894.66M 10-K · filed 2025-07-30 | |||
| 2025-02-28 | $221.00M 10-Q · filed 2026-04-09 | $220.98M 10-Q · filed 2025-04-09 | $452.26M derived: sum of 2 quarters · filed 2026-04-09 | $669.20M 10-Q · filed 2026-04-09 | $669.20M 10-Q · filed 2025-04-09 | $905.99M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-11-30 | $231.26M 10-Q · filed 2026-01-08 | $448.22M 10-Q · filed 2026-01-08 | $684.99M derived: sum of 3 quarters · filed 2026-07-30 | $913.81M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2024-08-31 | $216.96M 10-Q · filed 2025-10-09 | $453.74M derived: sum of 2 quarters · filed 2026-07-30 | $682.55M derived: sum of 3 quarters · filed 2026-07-30 | $912.18M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2024-05-31 | $236.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $465.58M derived: sum of 2 quarters · filed 2026-07-30 | $695.21M derived: sum of 3 quarters · filed 2026-07-30 | $924.20M 10-K · filed 2026-07-30 | $924.22M 10-K · filed 2024-07-30 | |||
| 2024-02-29 | $228.81M 10-Q · filed 2025-04-09 | $458.44M derived: sum of 2 quarters · filed 2025-04-09 | $687.43M 10-Q · filed 2025-04-09 | $929.24M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-11-30 | $229.63M 10-Q · filed 2025-01-15 | $458.62M 10-Q · filed 2025-01-15 | $700.43M derived: sum of 3 quarters · filed 2025-07-30 | $918.68M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-08-31 | $228.99M 10-Q · filed 2024-10-10 | $470.80M derived: sum of 2 quarters · filed 2025-07-30 | $689.05M derived: sum of 3 quarters · filed 2025-07-30 | $919.09M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2023-05-31 | $241.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $460.06M derived: sum of 2 quarters · filed 2025-07-30 | $690.10M derived: sum of 3 quarters · filed 2025-07-30 | $822.45M 10-K · filed 2025-07-30 | ||||
| 2023-02-28 | $218.25M 10-Q · filed 2024-04-09 | $448.29M derived: sum of 2 quarters · filed 2024-04-09 | $580.64M 10-Q · filed 2024-04-09 | $720.73M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-11-30 | $230.03M 10-Q · filed 2024-01-09 | $362.38M 10-Q · filed 2024-01-09 | $502.48M derived: sum of 3 quarters · filed 2024-07-30 | $630.72M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-08-31 | $132.35M 10-Q · filed 2023-10-10 | $272.44M derived: sum of 2 quarters · filed 2024-07-30 | $400.69M derived: sum of 3 quarters · filed 2024-07-30 | $531.20M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-05-31 | $140.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $268.34M derived: sum of 2 quarters · filed 2024-07-30 | $398.85M derived: sum of 3 quarters · filed 2024-07-30 | $527.16M 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | $128.24M 10-Q · filed 2023-04-04 | $258.76M derived: sum of 2 quarters · filed 2023-04-04 | $387.07M 10-Q · filed 2023-04-04 | $514.49M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-11-30 | $130.52M 10-Q · filed 2023-01-09 | $258.82M 10-Q · filed 2023-01-09 | $386.25M derived: sum of 3 quarters · filed 2023-08-15 | $502.96M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-08-31 | $128.31M 10-Q · filed 2022-09-30 | $255.73M derived: sum of 2 quarters · filed 2023-08-15 | $372.44M derived: sum of 3 quarters · filed 2023-08-15 | $487.44M derived: sum of 4 quarters · filed 2023-08-15 | ||||
| 2021-05-31 | $127.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-15 | $244.13M derived: sum of 2 quarters · filed 2023-08-15 | $359.13M derived: sum of 3 quarters · filed 2023-08-15 | $468.46M 10-K · filed 2023-08-15 | ||||
| 2021-02-28 | $116.71M 10-Q · filed 2022-04-01 | $231.71M derived: sum of 2 quarters · filed 2022-04-01 | $341.03M 10-Q · filed 2022-04-01 | $450.11M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2020-11-30 | $115.00M 10-Q · filed 2021-12-30 | $224.32M 10-Q · filed 2021-12-30 | $333.40M derived: sum of 3 quarters · filed 2022-07-27 | $433.27M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2020-08-31 | $109.33M 10-Q · filed 2021-09-30 | $218.40M derived: sum of 2 quarters · filed 2022-07-27 | $318.27M derived: sum of 3 quarters · filed 2022-07-27 | $426.07M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2020-05-31 | $109.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-27 | $208.94M derived: sum of 2 quarters · filed 2022-07-27 | $316.75M derived: sum of 3 quarters · filed 2022-07-27 | $418.17M 10-K · filed 2022-07-27 | ||||
| 2020-02-29 | $99.87M 10-Q · filed 2021-03-31 | $207.67M derived: sum of 2 quarters · filed 2021-03-31 | $309.10M 10-Q · filed 2021-03-31 | $418.86M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2019-11-30 | $107.80M 10-Q · filed 2020-12-29 | $209.23M 10-Q · filed 2020-12-29 | $318.99M derived: sum of 3 quarters · filed 2021-07-30 | $416.69M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2019-08-31 | $101.42M 10-Q · filed 2020-09-30 | $211.19M derived: sum of 2 quarters · filed 2021-07-30 | $308.89M derived: sum of 3 quarters · filed 2021-07-30 | $415.98M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2019-05-31 | $109.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-30 | $207.46M derived: sum of 2 quarters · filed 2021-07-30 | $314.56M derived: sum of 3 quarters · filed 2021-07-30 | $414.19M 10-K · filed 2021-07-30 | ||||
| 2019-02-28 | $97.70M 10-Q · filed 2020-04-03 | $204.80M derived: sum of 2 quarters · filed 2020-04-03 | $304.42M 10-Q · filed 2020-04-03 | $412.54M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2018-11-30 | $107.10M 10-Q · filed 2018-12-28 | $206.72M 10-Q · filed 2019-12-27 | $314.84M derived: sum of 3 quarters · filed 2020-07-30 | $409.75M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2018-08-31 | $99.63M 10-Q · filed 2019-09-26 | $207.75M derived: sum of 2 quarters · filed 2020-07-30 | $302.65M derived: sum of 3 quarters · filed 2020-07-30 | $403.31M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2018-05-31 | $108.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-30 | $203.02M derived: sum of 2 quarters · filed 2020-07-30 | $303.69M derived: sum of 3 quarters · filed 2020-07-30 | $397.93M 10-K · filed 2020-07-30 | $402.25M 10-K · filed 2018-07-27 | |||
| 2018-02-28 | $94.90M 10-Q · filed 2019-03-29 | $94.92M 10-Q · filed 2018-10-05 | $195.57M derived: sum of 2 quarters · filed 2019-03-29 | $289.81M 10-Q · filed 2019-03-29 | $289.79M 10-Q · filed 2018-10-05 | |||
| 2017-11-30 | $100.70M 10-Q · filed 2018-12-28 | $194.91M 10-Q · filed 2018-12-28 | $194.88M 10-Q · filed 2018-10-05 | |||||
| 2017-08-31 | $94.21M 10-Q · filed 2018-10-05 | |||||||
| 2017-05-31 | $358.28M 10-K · filed 2019-07-30 | $361.59M 10-K · filed 2018-07-27 | ||||||
| 2016-05-31 | $321.27M 10-K · filed 2018-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |